VTYX - VENTYX ALERT: Bragar Eagel & Squire P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ventyx Biosciences Inc. and Encourages Investors to Contact the Firm | Benzinga
NEW YORK, March 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ:VTYX) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired Ventyx common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about October 21, 2021 (the "IPO" or "Offering"); and/or (b) Ventyx securities between October 21, 2021 and November 6, 2023, both dates inclusive (the "Class Period"). Investors have until April 30, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases. The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. In 2022, Ventyx initiated a Phase 2 clinical trial of VTX958 for the treatment of moderate to severe plaque psoriasis (the "Phase 2 SERENITY Trial").
On September 29, 2021, Ventyx filed a registration statement on Form S-1 with the Securities and Exchange Commission ("SEC") in connection with the IPO, ...